| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
|
Kerr, Rachel S
|
|
2016
|
17 |
11 |
p. 1543-1557
|
artikel
|
| 2 |
A Good Death
|
Burki, Talha Khan
|
|
2016
|
17 |
11 |
p. 1496
|
artikel
|
| 3 |
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
|
Bottomley, Andrew
|
|
2016
|
17 |
11 |
p. e510-e514
|
artikel
|
| 4 |
A selective histone deacetylase inhibitor for myeloma
|
Pratt, Guy
|
|
2016
|
17 |
11 |
p. 1472-1474
|
artikel
|
| 5 |
Bevacizumab in colorectal cancer: it should have worked
|
Saltz, Leonard B
|
|
2016
|
17 |
11 |
p. 1469-1470
|
artikel
|
| 6 |
Biochemical and imaging surveillance in Li-Fraumeni syndrome
|
Raskind, Wendy H
|
|
2016
|
17 |
11 |
p. e472
|
artikel
|
| 7 |
Biochemical and imaging surveillance in Li-Fraumeni syndrome – Authors’ reply
|
Villani, Anita
|
|
2016
|
17 |
11 |
p. e473
|
artikel
|
| 8 |
Cancer drug safety: time to re-focus on tackling adverse effects
|
The Lancet Oncology,
|
|
2016
|
17 |
11 |
p. 1463
|
artikel
|
| 9 |
Cancer on board
|
Hellier, Rachel
|
|
2016
|
17 |
11 |
p. 1494
|
artikel
|
| 10 |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
|
Langer, Corey J
|
|
2016
|
17 |
11 |
p. 1497-1508
|
artikel
|
| 11 |
City 40
|
Burki, Talha Khan
|
|
2016
|
17 |
11 |
p. 1495
|
artikel
|
| 12 |
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
|
Hodi, F Stephen
|
|
2016
|
17 |
11 |
p. 1558-1568
|
artikel
|
| 13 |
Correction to Lancet Oncol 2016; 17: 1426–34
|
|
|
2016
|
17 |
11 |
p. e479
|
artikel
|
| 14 |
Daratumumab improves survival in multiple myeloma
|
Baker, Holly
|
|
2016
|
17 |
11 |
p. e480
|
artikel
|
| 15 |
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
|
Zhao, Shuang G
|
|
2016
|
17 |
11 |
p. 1612-1620
|
artikel
|
| 16 |
Diminished but not dead: chemotherapy for the treatment of NSCLC
|
Herbst, Roy S
|
|
2016
|
17 |
11 |
p. 1464-1465
|
artikel
|
| 17 |
Does an optimum treatment for high-risk low-grade gliomas exist?
|
Rudà, Roberta
|
|
2016
|
17 |
11 |
p. 1467-1469
|
artikel
|
| 18 |
European Society of Medical Oncology 2016 Congress
|
Landman, Allison
|
|
2016
|
17 |
11 |
p. 1491-1492
|
artikel
|
| 19 |
Fast-track approval of medicines in Australia
|
Nash, Lloyd
|
|
2016
|
17 |
11 |
p. 1487
|
artikel
|
| 20 |
24-gene predictor of response to postoperative irradiation
|
Bolla, Michel
|
|
2016
|
17 |
11 |
p. 1478-1480
|
artikel
|
| 21 |
Generic oncology drugs: are they all safe?
|
Yang, Y Tony
|
|
2016
|
17 |
11 |
p. e493-e501
|
artikel
|
| 22 |
HBV and HCV co-infection increases cancer risk in HIV patients
|
Tanday, Sanjay
|
|
2016
|
17 |
11 |
p. e484
|
artikel
|
| 23 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|
Reijneveld, Jaap C
|
|
2016
|
17 |
11 |
p. 1533-1542
|
artikel
|
| 24 |
HPV 16 in squamous cell carcinoma of 19th century tonsils
|
Benmoussa, Nadia
|
|
2016
|
17 |
11 |
p. e477-e478
|
artikel
|
| 25 |
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|
Rini, Brian I
|
|
2016
|
17 |
11 |
p. 1599-1611
|
artikel
|
| 26 |
Immunomodulatory treatment in urothelial cancer
|
Dreicer, Robert
|
|
2016
|
17 |
11 |
p. 1475-1477
|
artikel
|
| 27 |
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
|
Sun, Ying
|
|
2016
|
17 |
11 |
p. 1509-1520
|
artikel
|
| 28 |
In the shadow of disaster
|
Swain, Kelley
|
|
2016
|
17 |
11 |
p. 1493
|
artikel
|
| 29 |
Ipilimumab plus nivolumab for advanced melanoma
|
Hassel, Jessica C
|
|
2016
|
17 |
11 |
p. 1471-1472
|
artikel
|
| 30 |
Ipilimumab prolongs survival in advanced melanoma
|
Burki, Talha Khan
|
|
2016
|
17 |
11 |
p. e481
|
artikel
|
| 31 |
Is sidedness prognostically important across all stages of colorectal cancer?
|
Kerr, David J
|
|
2016
|
17 |
11 |
p. 1480-1482
|
artikel
|
| 32 |
NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma
|
Adam, Jane
|
|
2016
|
17 |
11 |
p. 1485-1486
|
artikel
|
| 33 |
NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
|
Umeweni, Nwamaka
|
|
2016
|
17 |
11 |
p. 1483-1484
|
artikel
|
| 34 |
Nivolumab for recurrent or metastatic head and neck cancer
|
Tanday, Sanjay
|
|
2016
|
17 |
11 |
p. e483
|
artikel
|
| 35 |
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
|
Sharma, Padmanee
|
|
2016
|
17 |
11 |
p. 1590-1598
|
artikel
|
| 36 |
No increase in childhood leukaemia near UK nuclear sites
|
Mayor, Susan
|
|
2016
|
17 |
11 |
p. 1488
|
artikel
|
| 37 |
Olaparib and ovarian cancer—overall survival outcomes
|
Kehoe, Sean
|
|
2016
|
17 |
11 |
p. 1474-1475
|
artikel
|
| 38 |
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
|
Ledermann, Jonathan A
|
|
2016
|
17 |
11 |
p. 1579-1589
|
artikel
|
| 39 |
Predicting cancer: can we? Should we?
|
Coburn, Cassandra
|
|
2016
|
17 |
11 |
p. 1494
|
artikel
|
| 40 |
Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?
|
Spiotto, Michael T
|
|
2016
|
17 |
11 |
p. 1465-1467
|
artikel
|
| 41 |
Ribociclib in HR-positive, HER2-negative breast cancer
|
Burki, Talha Khan
|
|
2016
|
17 |
11 |
p. e482
|
artikel
|
| 42 |
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
|
Yee, Andrew J
|
|
2016
|
17 |
11 |
p. 1569-1578
|
artikel
|
| 43 |
Risk of cancer in patients with polycystic kidney disease
|
Cachat, Francois
|
|
2016
|
17 |
11 |
p. e474
|
artikel
|
| 44 |
Risk of cancer in patients with polycystic kidney disease
|
Violo, Leano
|
|
2016
|
17 |
11 |
p. e475
|
artikel
|
| 45 |
Risk of cancer in patients with polycystic kidney disease – Authors’ reply
|
Yu, Tung-Min
|
|
2016
|
17 |
11 |
p. e476
|
artikel
|
| 46 |
Safety and efficacy of biosimilars in oncology
|
Schellekens, Huub
|
|
2016
|
17 |
11 |
p. e502-e509
|
artikel
|
| 47 |
Sarcoma and germ-line DICER1 mutations
|
de Kock, Leanne
|
|
2016
|
17 |
11 |
p. e470
|
artikel
|
| 48 |
Sarcoma and germ-line DICER1 mutations – Authors’ reply
|
Ballinger, Mandy L
|
|
2016
|
17 |
11 |
p. e471
|
artikel
|
| 49 |
21st century pharmacovigilance: efforts, roles, and responsibilities
|
Pitts, Peter J
|
|
2016
|
17 |
11 |
p. e486-e492
|
artikel
|
| 50 |
Sunitinib as adjuvant therapy for renal cell carcinoma
|
Baker, Holly
|
|
2016
|
17 |
11 |
p. e485
|
artikel
|
| 51 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|
Baumert, Brigitta G
|
|
2016
|
17 |
11 |
p. 1521-1532
|
artikel
|
| 52 |
58th ASTRO annual meeting
|
Lokody, Isabel
|
|
2016
|
17 |
11 |
p. 1489-1490
|
artikel
|
| 53 |
The Cancer Space Suit Art Project
|
Thomas, Laura
|
|
2016
|
17 |
11 |
p. 1496
|
artikel
|
| 54 |
Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar
|
Pal, Sumanta K
|
|
2016
|
17 |
11 |
p. 1477-1478
|
artikel
|
| 55 |
Vemurafenib for BRAF V600E-positive metastatic papillary thyroid cancer
|
Huillard, Olivier
|
|
2016
|
17 |
11 |
p. e468
|
artikel
|
| 56 |
Vemurafenib for BRAF V600E-positive metastatic papillary thyroid cancer – Authors' response
|
Brose, Marcia S
|
|
2016
|
17 |
11 |
p. e469
|
artikel
|
Tijdschrift beschrijving